Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16442330 | 0.81 | LPAR2 (0.47) | LPAR2SPRPOLBPIK3CGALDH1A1 | |
| SCHEMBL18711331 | 0.81 | LPAR2 (0.49) | LPAR2LMNASPRPOLBPIK3CG | |
| SCHEMBL7092512 | 0.81 | LPAR2 (0.47) | LPAR2LMNASPRPOLBPIK3CG | |
| SCHEMBL1233967 | 0.80 | PIK3CG (0.44) | MAPK1LMNASMN1; SMN2PIK3CGALDH1A1 | |
| SCHEMBL18711341 | 0.77 | SPR (0.47) | LPAR2SPRPOLBPIK3CGALDH1A1 | |
| SCHEMBL1939763 | 0.75 | PIK3CG (0.46) | LPAR2SPRPOLBPIK3CGALDH1A1 | |
| SCHEMBL1939762 | 0.75 | PIK3CG (0.46) | LPAR2SPRPOLBPIK3CGALDH1A1 | |
| SCHEMBL10125972 | 0.71 | PIK3CG (0.57) | SMN1; SMN2PIK3CGALDH1A1 | |
| SCHEMBL4854398 | 0.71 | PIK3CG (0.50) | SMN1; SMN2PIK3CGALDH1A1 | |
| SCHEMBL41794 | 0.71 | PIK3CG (0.59) | SMN1; SMN2PIK3CGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | MAPK1 581/4885LPAR2 772/4885LMNA 2367/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPK1 377/4885LPAR2 1047/4885LMNA 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.